Shoulder Innovations (NYSE:SI) Major Shareholder Sells $166,132.32 in Stock

Shoulder Innovations, Inc. (NYSE:SI) major shareholder Healthcare Holding B.V. Gilde sold 7,338 shares of the stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $22.64, for a total value of $166,132.32. Following the completion of the sale, the insider owned 2,214,302 shares of the company’s stock, valued at approximately $50,131,797.28. This trade represents a 0.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Healthcare Holding B.V. Gilde also recently made the following trade(s):

• On Thursday, August 6th, Healthcare Holding B.V. Gilde sold 2,095 shares of Shoulder Innovations stock. The stock was sold at an average price of $22.60, for a total value of $47,347.00.
• On Tuesday, August 4th, Healthcare Holding B.V. Gilde sold 99,812 shares of Shoulder Innovations stock. The shares were sold at an average price of $22.77, for a total transaction of $2,272,719.24.
• On Monday, August 3rd, Healthcare Holding B.V. Gilde sold 10,751 shares of Shoulder Innovations stock. The shares were sold at an average price of $22.71, for a total transaction of $244,155.21.
• On Friday, July 31st, Healthcare Holding B.V. Gilde sold 20,034 shares of Shoulder Innovations stock. The stock was sold at an average price of $22.73, for a total transaction of $455,372.82.
• On Thursday, July 30th, Healthcare Holding B.V. Gilde sold 28,245 shares of Shoulder Innovations stock. The stock was sold at an average price of $23.36, for a total value of $659,803.20.

Shoulder Innovations Stock Performance

Shares of NYSE:SI traded down $1.89 during trading on Friday, hitting $20.54. The stock had a trading volume of 286,871 shares, compared to its average volume of 93,468. Shoulder Innovations, Inc. has a 12-month low of $10.92 and a 12-month high of $24.59. The stock has a market capitalization of $426.06 million and a price-to-earnings ratio of -0.12. The company has a quick ratio of 10.04, a current ratio of 11.81 and a debt-to-equity ratio of 0.11. The stock has a 50-day simple moving average of $19.79 and a two-hundred day simple moving average of $16.04.

Shoulder Innovations (NYSE:SI) last issued its earnings results on Wednesday, May 13th. The company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.03. Shoulder Innovations had a negative return on equity of 35.11% and a negative net margin of 81.78%.The firm had revenue of $16.71 million for the quarter. On average, equities research analysts expect that Shoulder Innovations, Inc. will post -1.67 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on SI shares. Weiss Ratings upgraded shares of Shoulder Innovations from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday. Piper Sandler reiterated an “overweight” rating and set a $25.00 price objective (up from $19.00) on shares of Shoulder Innovations in a research note on Friday. UBS Group began coverage on Shoulder Innovations in a report on Tuesday, July 28th. They issued a “buy” rating and a $27.00 price objective for the company. Finally, BTIG Research upped their target price on Shoulder Innovations from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Shoulder Innovations currently has an average rating of “Moderate Buy” and an average target price of $23.33.

Shoulder Innovations News Summary

Here are the key news stories impacting Shoulder Innovations this week:

• Positive Sentiment: Analysts raised their targets: Piper Sandler reaffirmed its “overweight” rating and lifted its price target from $19 to $25, while BTIG Research raised its target from $24 to $26 and initiated a “buy” rating. These targets imply meaningful upside and may support investor sentiment. Benzinga analyst rating updates
• Positive Sentiment: Revenue growth remained strong: Second-quarter revenue increased approximately 56% year over year to $17.2 million, slightly exceeding estimates. Gross profit rose about 60%, indicating continued demand and improving product economics. Shoulder Innovations Q2 2026 earnings summary
• Positive Sentiment: Full-year guidance was raised: SI forecast fiscal-year revenue of $67 million to $69 million, broadly in line with the roughly $67.1 million consensus estimate. Management also highlighted 60% first-half revenue growth. Shoulder Innovations raises full-year outlook
• Neutral Sentiment: Liquidity appears adequate but is declining: The company ended the quarter with $24.5 million in cash and used $7.4 million in operating activities and $2.2 million in capital expenditures. Investors will likely monitor whether revenue growth can lead to improved cash generation.
• Negative Sentiment: Profitability remains a concern: SI reported an operating loss of about $10 million, a net loss of approximately $10.2 million, and diluted EPS near negative $0.49, missing some estimates. The company remains deeply unprofitable, increasing valuation sensitivity. Shoulder Innovations quarterly results
• Negative Sentiment: Major-holder selling may weigh on sentiment: Gilde Healthcare sold more than 110,000 shares in early August for roughly $2.5 million. Although it retains a substantial stake, the sales can raise concerns about near-term supply and insider conviction. Gilde Healthcare insider sale

Hedge Funds Weigh In On Shoulder Innovations

Large investors have recently made changes to their positions in the company. Deerfield Management Company L.P. acquired a new stake in Shoulder Innovations in the third quarter valued at approximately $6,056,000. Alyeska Investment Group L.P. acquired a new position in shares of Shoulder Innovations during the 3rd quarter worth approximately $5,667,000. Vanguard Group Inc. purchased a new position in shares of Shoulder Innovations during the 3rd quarter valued at approximately $1,836,000. Roubaix Capital LLC lifted its position in shares of Shoulder Innovations by 61.9% during the 1st quarter. Roubaix Capital LLC now owns 257,121 shares of the company’s stock valued at $3,736,000 after buying an additional 98,305 shares in the last quarter. Finally, Millennium Management LLC acquired a new stake in Shoulder Innovations in the 4th quarter valued at $1,316,000.

About Shoulder Innovations

Shoulder Innovations (NYSE:SI) is a medical device company focused on the design, development and commercialization of shoulder implant systems and related surgical instruments for orthopedic surgery. The company’s product portfolio includes modular shoulder prostheses, humeral and glenoid components, and instrumentation kits designed to facilitate both primary and revision shoulder arthroplasty procedures. Emphasizing a patient-centric approach, Shoulder Innovations works to offer implant solutions that aim to restore mobility and reduce post-operative complications.

In addition to its core implant offerings, Shoulder Innovations provides comprehensive clinical support and training programs for surgeons and operating room teams.